Compare · IQV vs PRAH
IQV vs PRAH
Side-by-side comparison of IQVIA Holdings Inc. (IQV) and PRA Health Sciences, Inc. (PRAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IQV and PRAH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- IQV carries a market cap of $43.63B.
- IQV has hit the wire 8 times in the past 4 weeks while PRAH has been quiet.
- IQV has more recent analyst coverage (25 ratings vs 0 for PRAH).
- Company
- IQVIA Holdings Inc.
- PRA Health Sciences, Inc.
- Price
- -
- -
- Market cap
- $43.63B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- 2014
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 0
IQVIA Holdings Inc.
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Latest IQV
- Officer Sherbet Eric exercised 8,436 shares at a strike of $131.82, sold $1,239,678 worth of shares (4,446 units at $278.83) and returned $1,112,173 worth of shares to the company (3,990 units at $278.74) (SEC Form 4)
- Director Wims Morris Leslie was granted 125 deferred shares (SEC Form 4)
- Director Goggins Colleen A was granted 144 deferred shares (SEC Form 4)
- Director Fasano Jim was granted 154 deferred shares (SEC Form 4)
- Director Danhakl John G was granted 134 deferred shares (SEC Form 4)
- SEC Form 10-Q filed by IQVIA Holdings Inc.
- SEC Form 8-K filed by IQVIA Holdings Inc.
- IQVIA Reports Third-Quarter 2026 Results
- IQVIA Selects Veeva Clinical Operations Applications
- IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
Latest PRAH
- Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
- SEC Form SC 13G filed by PRA Health Sciences, Inc.
- SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)
- SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Young Matthew P. returned 7,127 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Stettin Glen D. returned 1,049 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: MOMTAZEE JAMES C returned 3,521 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Dickinson Alexander George returned 5,407 units of Common Stock to the company, closing all direct ownership in the company